Open AccessHemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy
Author(s) -
Asha Kallianpur,
Todd Hulgan,
Jeffrey A. Canter,
Marylyn D. Ritchie,
Jonathan L. Haines,
Gregory K. Robbins,
Robert W. Shafer,
David B. Clifford,
David W. Haas
Publication year - 2006
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/01.aids.0000237366.56864.3c
Subject(s) - stavudine , didanosine , efavirenz , lamivudine , medicine , zidovudine , nelfinavir , peripheral neuropathy , odds ratio , gastroenterology , transferrin saturation , immunology , viral load , anemia , viral disease , endocrinology , iron deficiency , antiretroviral therapy , diabetes mellitus , human immunodeficiency virus (hiv) , hepatitis b virus , virus
Peripheral neuropathy (PN) often complicates nucleoside reverse transcriptase inhibitor (NRTI) therapy of HIV infection and may involve mitochondrial dysfunction. Since iron deficiency is associated with some types of PN, and iron is essential for mitochondrial function, we tested the hypothesis that hemochromatosis (HFE) gene mutations influence susceptibility to NRTI-induced PN.